HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives $20.88 Average Price Target from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been given an average rating of “Hold” by the six ratings firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.8750.

A number of equities analysts recently issued reports on HCM shares. Weiss Ratings reissued a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. Wall Street Zen upgraded HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th. Finally, Jefferies Financial Group upgraded HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th.

Institutional Trading of HUTCHMED

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC grew its position in shares of HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after buying an additional 124,771 shares during the period. UBS Group AG boosted its stake in HUTCHMED by 112.8% during the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares in the last quarter. Amundi grew its holdings in HUTCHMED by 41.9% in the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after purchasing an additional 65,898 shares during the period. ABN Amro Investment Solutions purchased a new stake in HUTCHMED in the second quarter worth about $962,000. Finally, Tema Etfs LLC bought a new position in shares of HUTCHMED during the second quarter valued at approximately $641,000. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Stock Down 1.9%

Shares of NASDAQ HCM opened at $14.89 on Thursday. The firm has a fifty day simple moving average of $14.34 and a two-hundred day simple moving average of $15.26. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. HUTCHMED has a 12 month low of $11.51 and a 12 month high of $19.50.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.